Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort

摘要: Abstract Aims We explored the risks associated with metformin plus sulfonylurea (MET + SU) or MET a dipeptidyl peptidase-4 inhibitor (MET + DPP4i) for hypoglycemia, cardiovascular disease (CVD) events and all-cause mortality in type 2 diabetes (T2D) patients comorbidities. Methods This retrospective cohort study is based on South Korean National Health Insurance Service–National Sample Cohort, enrolling T2D one more diabetes-related comorbidities who switched from monotherapy to MET + SU MET + DPP4i between July 1, 2008 December 31, 2013. The risk of CVD was examined using Cox's proportional hazard modeling propensity score matching. Results Overall, 5693 mean 2.6 addition were included. Compared MET + SU, treatment lower mortality; adjusted HRs (95% CI), 0.39 (0.18–0.83), 0.72 (0.54–0.97), 0.64 (0.39–1.05), respectively. Propensity matching showed comparable results. In further subgroup analyses according comorbidity number, less compared MET + SU. increased complex comorbid status. Conclusions comorbidities, independent number A status increases this effect.